|
Post by lakers on Dec 9, 2016 12:52:41 GMT -5
I agree with Hillsave. That's called conflict of interest. That's why Sny never bothered trying to improve label and start pediatric trials ASAP. More than Two years have been wasted.
IMHO, Novo could pick up the baton dropped by Sny. The relay will continue.
Afrezza is promotionally sensitive. Afrezza needs sufficient budget from a deep pocket parent for DTC, TV Ads.
|
|
|
Post by bradleysbest on Dec 9, 2016 13:33:23 GMT -5
The "potential" is there for someone in big pharma to pick up the ball & run with it.... We can only hope!
|
|
|
Post by careful2invest on Dec 9, 2016 13:57:02 GMT -5
The "potential" is there for someone in big pharma to pick up the ball & run with it.... We can only hope! That would definitely fastrack AFREZZA and guarantee success, and after so many years of owning MNKD, that would be my preference. But even if that is not in the cards, AFREZZA is definitly gaining ground. Albeit slowly, but word IS getting out of what AFREZZA can do for a person suffering with Diabetes. In any case, I will be here to see it through. GLTA TRUE LONGS!
|
|
|
Post by otherottawaguy on Dec 9, 2016 14:09:15 GMT -5
Hillsave:
It might make for an interesting conversation with your Endo to see why he was so against Afrezza. Since you didn't punch his lights out, I am assuming you are still on talking terms.
I(we) would be very interested to hear what the little birds may have been whispering to him. Prepare to look at his body language when you first ask the question.
Would be interested to know if your results on Afrezza have pretty much silenced "des oiseaux" (birds: in french if you get the underlying meaning) in his mind and if he is now prescribing to others based upon your family's results.
Best wishes in your fight,
OOG
|
|
|
Post by hillsave on Dec 9, 2016 17:05:51 GMT -5
I agree with Hillsave. That's called conflict of interest. That's why Sny never bothered trying to improve label and start pediatric trials ASAP. More than Two years have been wasted. IMHO, Novo could pick up the baton dropped by Sny. The relay will continue. Afrezza is promotionally sensitive. Afrezza needs sufficient budget from a deep pocket parent for DTC, TV Ads. DTC TV ads are expected to begin in the second Q of 2017. This was discussed on the last CC by Mike.
|
|
|
Post by agedhippie on Dec 9, 2016 18:34:35 GMT -5
I agree with Hillsave. That's called conflict of interest. That's why Sny never bothered trying to improve label and start pediatric trials ASAP. More than Two years have been wasted. IMHO, Novo could pick up the baton dropped by Sny. The relay will continue. Afrezza is promotionally sensitive. Afrezza needs sufficient budget from a deep pocket parent for DTC, TV Ads. The pediatric trial is sitting out there suspended. It was started by Sanofi and I think part of it was completed with recruitment for the second round outstanding. The ball is in Mannkind's court and has been since March - they could have restarted recruitment at any time. I cannot see Novo picking up Afrezza since they abandoned their own inhaled insulin. If some one picks it up my feeling is that it will be a pharma that is a minor player in this space as it buys them entry. Afrezza needs insurance cover before all else. Big bucks campaigns are not going to do it if the first thing the doctor says is that it isn't covered by insurance at tier 2. People might pay once they have used it, but they will never reach that point as things stand.
|
|
|
Post by mnholdem on Dec 9, 2016 18:58:30 GMT -5
Forgive me if I lapse into a baba-like story, and compare this scenario to The GodFather (arguably the greatest movie of all time) but asking Novo to "pick up the baton" to market Afrezza is like asking any one of the Five Families to back a drug that could significantly cut into their territories...perhaps even put them out of business. Each one would all be willing to make the deal and then shoot MNKD in the head at the first opportunity to eliminate a perceived threat. The other heads of the families (aka BPs) would compliment whoever pulled the trigger.
Sanofi (Corleone) played it smart. The other families? I wouldn't trust any of them with Afrezza. There would have to be some kind of iron-clad guarantee.
|
|
|
Post by hillsave on Dec 9, 2016 21:45:05 GMT -5
Hillsave: It might make for an interesting conversation with your Endo to see why he was so against Afrezza. Since you didn't punch his lights out, I am assuming you are still on talking terms. I(we) would be very interested to hear what the little birds may have been whispering to him. Prepare to look at his body language when you first ask the question. Would be interested to know if your results on Afrezza have pretty much silenced "des oiseaux" (birds: in french if you get the underlying meaning) in his mind and if he is now prescribing to others based upon your family's results. Best wishes in your fight, OOG In my Endo's (Large) practice in Long Island, NY he primarily sees T2 Diabetics and those with other issues that an Endo would treat. He doesn't prescribe Insulin for any of his T2 Patients. I'm the first with Afrezza and the first with Insulin. He usually treats his Patients with Metformin. I have a full bottle of it. Never took it. At first when we met he said he would never write a letter of medical necessity because in his opinion he could treat me with Metformin or other drugs and get the same results as Afrezza. Ignorance is Bliss. Well after watching my A1C go from 6.4 to 5.7 to 5.5 he wrote the best letter and helped me write my own personal letter of Medical Necessity.Complete 360. He and his assistant even had lunch with with the sales rep and area manager from MANNKIND. He was given samples to try on his T1 patients. I haven't seen him in 2 months so we haven't had a chance to speak. He also is a little full of himself and thinks he wrote the book. Hard to teach an old dog new tricks. He's been around for a while. The younger more progressive Endo's are the ones that are willing to try new drugs. I know first hand that there are many Endo's around the country that are thrilled with the performance and ease of use with Afrezza. Both personally (those that are Diabetic themselves and professionally that are currently using Afrezza to treat both T1 & T2. Aaron K The Medical Director of JDRF had been using Afrezza himself for T1 and is thrilled with the results. My x wife is the Chair Person for the Walk -A -Thons for JDRF and she told Aaron over 18 months ago how well our son ( T1 ) was doing with his control using Afrezza. Hopefully the Pediatric trials will start soon. I know many parents that can't wait to be able to give their kids Afrezza rather than have to chase them around to give them 5-7 shots a day. Ouchhhhh
|
|